NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
DualityBio Inc.
Tanabe Pharma America, Inc.
Numab Therapeutics AG
Intensity Therapeutics, Inc.
Simcha IL-18, Inc.
Cancer Research UK
Icahn School of Medicine at Mount Sinai
NBE-Therapeutics AG
Kineta Inc.
University of California, San Francisco
Hanmi Pharmaceutical Company Limited
Hadassah Medical Organization